Humeau Laurent 4

4 · INOVIO PHARMACEUTICALS, INC. · Filed Feb 27, 2026

AI-generated summary of this filing

Updated Feb 27, 2026

INOVIO (INO) CSO Laurent Humeau Receives Shares on RSU Vesting

What Happened

Laurent Humeau, Chief Scientific Officer of INOVIO Pharmaceuticals (INO), had restricted stock units (RSUs) vest on February 26, 2026. A total of 12,376 RSUs (5,010 from a 2024 grant and 7,366 from a 2025 grant) were settled into shares. The company withheld 5,098 shares to satisfy payroll/tax withholding, valued at $1.79 per share for withholding purposes (total withholding ≈ $9,126). Net shares issued to Humeau were about 7,278. There was no open-market sale reported — this was an RSU settlement, not a sale.

Key Details

Transaction date: February 26, 2026; Form 4 filed February 27, 2026.
Vested/converted (M code): 5,010 shares (2024 grant) and 7,366 shares (2025 grant) → total 12,376 shares.
Tax-withholding (F code): 2,064 and 3,034 shares withheld at $1.79/share, proceeds $3,695 and $5,431 (total ≈ $9,126).
Net shares received by Humeau ≈ 7,278 (12,376 vested − 5,098 withheld).
Footnotes: Vesting schedules — 15,029 RSUs granted 2/28/2024 (staggered vesting through 2027) and 22,098 RSUs granted 2/27/2025 (staggered vesting through 2028). Vested RSUs can be settled in stock, cash, or both. The F entries represent shares withheld to cover tax obligations.
Shares owned after the transaction: not specified in the provided excerpt — see the full Form 4 for total beneficial ownership.

Context

This was a routine RSU vesting and settlement (codes M = conversion/exercise of derivative; F = shares withheld for taxes). Withholding of shares to cover taxes is common and is not the same as an open-market sale. No 10b5-1 plan or late-filing flag was indicated in the provided details.

Form 4

Period: 2026-02-26

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-26+5,010→ 37,632 total
Tax Payment
Common Stock
[F2]
2026-02-26$1.79/sh−2,064$3,695→ 35,568 total
Exercise/Conversion
Common Stock
[F3]
2026-02-26+7,366→ 42,934 total
Tax Payment
Common Stock
[F4]
2026-02-26$1.79/sh−3,034$5,431→ 39,900 total
Exercise/Conversion
Restricted Stock Unit
[F1]
2026-02-26−5,010→ 5,009 total
→ Common Stock (5,010 underlying)
Exercise/Conversion
Restricted Stock Unit
[F3]
2026-02-26−7,366→ 14,732 total
→ Common Stock (7,366 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units granted on February 28, 2024 was as follows: 5,010 shares vested on February 26, 2025; 5,010 shares vested on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
[F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
[F3]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 22,098 restricted stock units granted on February 27, 2025 was as follows: 7,366 shares vested on February 26, 2026; 7,366 shares will vest on February 26, 2027; 7,366 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
[F4]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein.

Signature

/s/ Laurent Humeau|2026-02-27

1 file